# PRAMEF3 (Q-17): sc-69316



The Power to Question

#### **BACKGROUND**

Several tumor-associated antigen families, such as MAGE, GAGE, PRAME and BAGE, are of particular interest in tumor immunology because their expression, with the exception of testis and fetal tissues, seems to be restricted to tumor cells. The MAGE, BAGE and GAGE genes code for distinct antigens that are recognized by autologous cytolytic T lymphocytes. Many of these antigens represent suitable targets for tumor immunotherapy, since their expression in human melanoma cells is common and highly specific. PRAME (preferentially expressed antigen of melanoma) is a melanoma antigen recognized by cytotoxic T cells (CTLs) and is expressed in a variety of cancer cells, including leukemic cells. The PRAME gene is expressed at a high level in a very large fraction of tumors, such as melanomas, non small-cell lung carcinomas, sarcomas, head and neck tumors and renal carcinomas. Therefore, PRAME is a candidate for tumor immunotherapy, even though it is expressed at low levels in certain normal tissues.

## **REFERENCES**

- 1. Li, J., et al. 1996. Expression of BAGE, GAGE, and MAGE genes in human gastric carcinoma. Clin. Cancer Res. 2: 1619-1625.
- Kirkin, A.F., et al. 1998. Melanoma-associated antigens recognized by cytotoxic T lymphocytes. APMIS 106: 665-679.
- van Baren, N., et al. 1998. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br. J. Haematol. 102: 1376-1379.
- Dalerba, P., et al. 1998. High homogeneity of MAGE, BAGE, GAGE, tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: implications for protocol design of therapeutic antigen-specific vaccination strategies. Int. J. Cancer 77: 200-204.
- 5. Põld, M., et al. 1999. Identification of a new, unorthodox member of the MAGE gene family. Genomics 59: 161-167.
- Matsushita, M., et al. 2001. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br. J. Haematol. 112: 916-926.

# CHROMOSOMAL LOCATION

Genetic locus: PRAMEF22/PRAMEF3/PRAMEF19/PRAMEF18 (human) mapping to 1p36.21.

# SOURCE

PRAMEF3 (0-17) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of PRAMEF3 of human origin.

#### **PRODUCT**

Each vial contains 200  $\mu g$  lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-69316 P, (100  $\mu$ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

#### **APPLICATIONS**

PRAMEF3 (0-17) is recommended for detection of PRAMEF3, PRAMEF18, PRAMEF19 and PRAMEF22 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2  $\mu$ g per 100-500  $\mu$ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).


Molecular Weight of PRAMEF3: 55 kDa.

Positive Controls: HeLa whole cell lysate: sc-2200, Jurkat whole cell lysate: sc-2204 or NTERA-2 cl.D1 whole cell lysate: sc-364181.

#### **RECOMMENDED SECONDARY REAGENTS**

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

# DATA



PRAMEF3 (Q-17): sc-69316. Western blot analysis of PRAMEF3 expression in NTERA-2 cl.D1 (A), HeLa (B) and Jurkat (C) whole cell lysates.

#### **STORAGE**

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

### **PROTOCOLS**

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com